rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2020-02-15rpcardio-2131Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯAtrial Fibrillation: Development Mechanisms, Approaches and Prospects of TherapyФибрилляция предсердий: механизмы развития, подходы и перспективы терапииСапельниковО. В.SapelnikovO. V.

Сапельников Олег Валерьевич – доктор медицинских наук, руководитель лаборатории хирургических и рентгенхирургических методов лечения нарушений ритма сердца, отдел сердечно-сосудистой хирургии

121552, Москва, 3-я Черепковская ул., 15А

Oleg V. Sapelnikov – MD, PhD, Head of Laboratory of Interventional Treatment of Heart Rhythm Disorders, Department of Cardiovascular Surgery

 

КуликовА. А.KulikovA. A.

Куликов Алексей Алексеевич – младший научный сотрудник, отдел сердечно-сосудистой хирургии

121552, Москва, 3-я Черепковская ул., 15А

Aleksey A. Kulikov – Junior Researcher, Department of Cardiovascular Surgery

Tretya Cherepkovskaya 15а, Moscow, 121552

Zeart@mail.ruЧеркашинД. И.CherkashinD. I.

Черкашин Дмитрий Игоревич – кандидат медицинских наук, сердечно-сосудистый хирург, отдел сердечно-сосудистой хирургии

121552, Москва, 3-я Черепковская ул., 15А

Dmitry I. Cherkashin – MD, PhD, Cardiovascular Surgeon, Department of Cardiovascular Surgery

Tretya Cherepkovskaya 15а, Moscow, 121552

ГришинИ. Р.GrishinI. R.

Гришин Игорь Романович – кандидат медицинских наук, сердечно-сосудистый хирург, отдел сердечно-сосудистой хирургии

121552, Москва, 3-я Черепковская ул., 15А

Igor R. Grishin – MD, PhD, Cardiovascular Surgeon, Department of Cardiovascular Surgery

Tretya Cherepkovskaya 15а, Moscow, 121552

НиколаеваО. А.NikolaevaO. A.

Николаева Ольга Андреевна – младший научный сотрудник, лаборатория хирургических и рентгенхирургических методов лечения нарушений ритма сердца, отдел сердечно-сосудистой хирургии

121552, Москва, 3-я Черепковская ул., 15А

Olga A. Nikolaeva – Junior Researcher, Laboratory of Interventional Treatment of Heart Rhythm Disorders, Department of Cardiovascular Surgery

Tretya Cherepkovskaya 15а, Moscow, 121552

АкчуринР. С.AkchurinR. S.

Акчурин Ренат Сулейманович – доктор медицинских наук, профессор, академик РАН, руководитель отдела сердечно-сосудистой хирургии, заместительгенерального директора по хирургии

121552, Москва, 3-я Черепковская ул., 15А

Renat S. Akchurin – MD, PhD, Professor, Academician of the Russian Academy of Sciences, Head of Department of Cardiovascular Surgery, Deputy Director General for Surgery

Tretya Cherepkovskaya 15а, Moscow, 121552

Национальный медицинский исследовательский центр кардиологииRussian FederationНациональный медицинский исследовательский центр кардиологииРоссияNational Medical Research Center of CardiologyRussian Federation202001032020161118125Copyright © Sapelnikov O.V., Kulikov A.A., Cherkashin D.I., Grishin I.R., Nikolaeva O.A., Akchurin R.S., 20202020Сапельников О.В., Куликов А.А., Черкашин Д.И., Гришин И.Р., Николаева О.А., Акчурин Р.С.Sapelnikov O.V., Kulikov A.A., Cherkashin D.I., Grishin I.R., Nikolaeva O.A., Akchurin R.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/2131

Atrial fibrillation (AF) is the most common arrhythmia. It is diagnosed in more than 33 million people worldwide and is the leading cause of hospitalization for arrhythmias. AF is characterized by fast and irregular atrial activation without discrete P-waves at a surface electrocardiography. AF pathophysiological mechanisms are very complex and include the dynamic interaction between arrhythmia substrate and triggers. Consequently, the clinical search for effective therapeutic targets should include the entire process of the onset and progression of the disease: from the first paroxysms to the development of a stable permanent form of AF.

Фибрилляция предсердий (ФП) является наиболее распространенным нарушением ритма сердца. Она диагностирована у более 33 миллионов людей во всем мире, и является главной причиной госпитализаций по поводу аритмий. ФП характеризуется быстрой и нерегулярной активацией предсердий без дискретных Р-волн при поверхностной электрокардиографии. Патофизиологические механизмы ФП очень сложные, включают в себя динамическое взаимодействие между многими звеньями, среди которых субстрат аритмии, триггеры и факторы, поддерживающие ее персистирование. Исходя из этого, клинический поиск эффективных терапевтических мишеней должен быть направлен на весь процесс возникновения и прогрессирования заболевания: от первых пароксизмов до развития устойчивой постоянной формы ФП.

фибрилляция предсердийионные каналыремоделирование«upstream» терапияatrial fibrillationion channelsremodelingupstream therapyReferencesChugh S.S., Havmoeller R., Narayanan K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. DOI:10.1161/CIRCULATIONAHA.113.005119.Chugh S.S., Havmoeller R., Narayanan K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. DOI:10.1161/CIRCULATIONAHA.113.005119.Padfield G.J., Steinberg C., Swampillai J. Progression of paroxysmal to persistent atrial fibrillation: 10year follow-up in the Canadian Registry of Atrial Fibrillation. Heart Rhythm. 2017;14(6):801-7. DOI:10.1016/j.hrthm.2017.01.038.Padfield G.J., Steinberg C., Swampillai J. Progression of paroxysmal to persistent atrial fibrillation: 10year follow-up in the Canadian Registry of Atrial Fibrillation. Heart Rhythm. 2017;14(6):801-7. DOI:10.1016/j.hrthm.2017.01.038.Jalife J., Kaur K. Atrial remodeling, fibrosis, and atrial fibrillation. Trends Cardiovasc Med. 2015;25(6):475-84. DOI:10.1016/j.tcm.2014.12.015.Jalife J., Kaur K. Atrial remodeling, fibrosis, and atrial fibrillation. Trends Cardiovasc Med. 2015;25(6):475-84. DOI:10.1016/j.tcm.2014.12.015.de Vos C.B., Pisters R., Nieuwlaat R., et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis.J Am Coll Cardiol. 2010;55(8):725-31. DOI:10.1016/j.jacc.2009.11.040.de Vos C.B., Pisters R., Nieuwlaat R., et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis.J Am Coll Cardiol. 2010;55(8):725-31. DOI:10.1016/j.jacc.2009.11.040.Voigt N., Trausch A., Knaut M., et al. Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(5):472-80. DOI:10.1161/CIRCEP.110.954636.Voigt N., Trausch A., Knaut M., et al. Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(5):472-80. DOI:10.1161/CIRCEP.110.954636.Heijman J., Voigt N., Nattel S., Dobrev D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114(9):1483-99. DOI:10.1161/CIRCRESAHA.114.302226.Heijman J., Voigt N., Nattel S., Dobrev D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114(9):1483-99. DOI:10.1161/CIRCRESAHA.114.302226.Martins R.P., Kaur K., Hwang E., et al. Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation. Circulation. 2014;129(14):1472-82. DOI:10.1161/CIRCULATIONAHA.113.004742.Martins R.P., Kaur K., Hwang E., et al. Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation. Circulation. 2014;129(14):1472-82. DOI:10.1161/CIRCULATIONAHA.113.004742.Deshmukh A., Barnard J., Sun H., et al. Left atrial transcriptional changes associated with atrial fibrillation susceptibility and persistence. Circ Arrhythm Electrophysiol. 2015;8(1):32-41. DOI:10.1161/CIRCEP.114.001632 .Deshmukh A., Barnard J., Sun H., et al. Left atrial transcriptional changes associated with atrial fibrillation susceptibility and persistence. Circ Arrhythm Electrophysiol. 2015;8(1):32-41. DOI:10.1161/CIRCEP.114.001632 .Mancarella S., Yue Y., Karnabi E., et al. Impaired Ca2+ homeostasis is associated with atrial fibrillation in the alpha1D L-type Ca2+ channel KO mouse. Am J Physiol Heart Circ Physiol. 2008;295(5):H201724. DOI:10.1152/ajpheart.00537.2008.Mancarella S., Yue Y., Karnabi E., et al. Impaired Ca2+ homeostasis is associated with atrial fibrillation in the alpha1D L-type Ca2+ channel KO mouse. Am J Physiol Heart Circ Physiol. 2008;295(5):H201724. DOI:10.1152/ajpheart.00537.2008.Sanders P., Berenfeld O., Hocini M., et al. Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans. Circulation. 2005;112(6):789-97. DOI:10.1161/CIRCULATIONAHA.104.517011.Sanders P., Berenfeld O., Hocini M., et al. Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans. Circulation. 2005;112(6):789-97. DOI:10.1161/CIRCULATIONAHA.104.517011.Matsushima S., Tsutsui H., Sadoshima J. Physiological and pathological functions of NADPH oxidases during myocardial ischemia-reperfusion. Trends Cardiovasc Med. 2014;24(5):202-5. DOI:10.1016/j.tcm.2014.03.003.Matsushima S., Tsutsui H., Sadoshima J. Physiological and pathological functions of NADPH oxidases during myocardial ischemia-reperfusion. Trends Cardiovasc Med. 2014;24(5):202-5. DOI:10.1016/j.tcm.2014.03.003.Lavall D., Selzer C., Schuster P., et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem. 2014;289(10):6656-68. DOI:10.1074/jbc.M113.519256.Lavall D., Selzer C., Schuster P., et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem. 2014;289(10):6656-68. DOI:10.1074/jbc.M113.519256.Takemoto Y., Ramirez R.J., Kaur K., et al. Eplerenone reduces atrial fibrillation burden without preventing atrial electrical remodeling. J Am CollCardiol. 2017;70(23):2893-2905. DOI:10.1016/j.jacc.2017.10.014.Takemoto Y., Ramirez R.J., Kaur K., et al. Eplerenone reduces atrial fibrillation burden without preventing atrial electrical remodeling. J Am CollCardiol. 2017;70(23):2893-2905. DOI:10.1016/j.jacc.2017.10.014.Pandit S.V., Jalife J. Rotors and the dynamics of cardiac fibrillation. Circ Res. 2013;112(5):849-62. DOI:10.1161/CIRCRESAHA.111.300158.Pandit S.V., Jalife J. Rotors and the dynamics of cardiac fibrillation. Circ Res. 2013;112(5):849-62. DOI:10.1161/CIRCRESAHA.111.300158.Fraccarollo D., Berger S., Galuppo P., et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation. 2011 F;123(4):400-8. DOI:10.1161/CIRCULATIONAHA.110.983023.Fraccarollo D., Berger S., Galuppo P., et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation. 2011 F;123(4):400-8. DOI:10.1161/CIRCULATIONAHA.110.983023.Zannad F., McMurray J.J., Krum H., et al.Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. DOI:10.1056/NEJMoa1009492.Zannad F., McMurray J.J., Krum H., et al.Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. DOI:10.1056/NEJMoa1009492.Rienstra M., Hobbelt A.H., Alings M., Tijssen J.G.P., et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J. 2018;39(32):2987-2996. DOI:10.1093/eurheartj/ehx739.Rienstra M., Hobbelt A.H., Alings M., Tijssen J.G.P., et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J. 2018;39(32):2987-2996. DOI:10.1093/eurheartj/ehx739.GISSI-AF Investigators, Disertori M., Latini R., Barlera S., Franzosi M.G., et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360(16):1606-17. DOI:10.1056/NEJMoa0805710.GISSI-AF Investigators, Disertori M., Latini R., Barlera S., Franzosi M.G., et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360(16):1606-17. DOI:10.1056/NEJMoa0805710.Takemoto Y., Slough D.P., Meinke G., et al. Structural basis for the antiarrhythmic blockade of a potassium channel with a small molecule. FASEB J. 2018;32(4):1778-93. DOI:10.1096/fj.201700349R.Takemoto Y., Slough D.P., Meinke G., et al. Structural basis for the antiarrhythmic blockade of a potassium channel with a small molecule. FASEB J. 2018;32(4):1778-93. DOI:10.1096/fj.201700349R.Takemoto Y., Ramirez R.J., Yokokawa M., et al. Galectin-3 regulates atrial fibrillation remodeling and predicts catheter ablation outcomes. JACC Basic Transl Sci. 2016;1(3):143-54.Takemoto Y., Ramirez R.J., Yokokawa M., et al. Galectin-3 regulates atrial fibrillation remodeling and predicts catheter ablation outcomes. JACC Basic Transl Sci. 2016;1(3):143-54.Mackinnon A.C., Gibbons M.A., Farnworth S.L., et al. Regulation of transforming growth factor-β1driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185(5):537-46. DOI:10.1164/rccm.201106-0965OC.Mackinnon A.C., Gibbons M.A., Farnworth S.L., et al. Regulation of transforming growth factor-β1driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185(5):537-46. DOI:10.1164/rccm.201106-0965OC.Salvador-Montañés O., Gómez-Gallanti A., Garofalo D., et al. Polyunsaturated fatty acids in atrial fibrillation: looking for the proper candidates. Front Physiol. 2012;3:370. DOI:10.3389/fphys.2012.00370.Salvador-Montañés O., Gómez-Gallanti A., Garofalo D., et al. Polyunsaturated fatty acids in atrial fibrillation: looking for the proper candidates. Front Physiol. 2012;3:370. DOI:10.3389/fphys.2012.00370.Kuhn E.W., Liakopoulos O.J., Stange S., et al. Preoperative statin therapy in cardiac surgery: a metaanalysis of 90,000 patients. Eur J Cardiothorac Surg. 2014;45(1):17-26. DOI:10.1093/ejcts/ezt181.Kuhn E.W., Liakopoulos O.J., Stange S., et al. Preoperative statin therapy in cardiac surgery: a metaanalysis of 90,000 patients. Eur J Cardiothorac Surg. 2014;45(1):17-26. DOI:10.1093/ejcts/ezt181.Zhang X., Zhang S., Li Y., et al. Association of obesity and atrial fibrillation among middle-aged and elderly Chinese. Int J Obes (Lond). 2009;33(11):1318-25. DOI:10.1038/ijo.2009.157.Zhang X., Zhang S., Li Y., et al. Association of obesity and atrial fibrillation among middle-aged and elderly Chinese. Int J Obes (Lond). 2009;33(11):1318-25. DOI:10.1038/ijo.2009.157.Abed H.S., Wittert G.A., Leong D.P., et al. Effect of weight reduction and cardiomelabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310(19):2050-60. DOI:10.1001/jama.2013.280521.Abed H.S., Wittert G.A., Leong D.P., et al. Effect of weight reduction and cardiomelabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310(19):2050-60. DOI:10.1001/jama.2013.280521.Pathak R.K., Elliott A., Middeldorp M.E., et al. Impact of CARDIO respiratory FITness on Arrhythmia Recurrence in Obese Individuals with Atrial Fibrillation: The CARDIO-FIT Study. J Am Coll Cardiol. 2015;66(9):985-96. DOI:10.1016/j.jacc.2015.06.488.Pathak R.K., Elliott A., Middeldorp M.E., et al. Impact of CARDIO respiratory FITness on Arrhythmia Recurrence in Obese Individuals with Atrial Fibrillation: The CARDIO-FIT Study. J Am Coll Cardiol. 2015;66(9):985-96. DOI:10.1016/j.jacc.2015.06.488.Iacobellis G., Bianco A.C. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011;22(11):450-7. DOI:10.1016/j.tem.2011.07.003.Iacobellis G., Bianco A.C. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011;22(11):450-7. DOI:10.1016/j.tem.2011.07.003.Haemers P., Hamdi H., Guedj K., et al. Atrial fibrillation is associated with the fibrotic remodelling of adipose tissue in the subepicardium of human and sheep atria. Eur Heart J. 2017;38(1):53-61. DOI:10.1093/eurheartj/ehv625.Haemers P., Hamdi H., Guedj K., et al. Atrial fibrillation is associated with the fibrotic remodelling of adipose tissue in the subepicardium of human and sheep atria. Eur Heart J. 2017;38(1):53-61. DOI:10.1093/eurheartj/ehv625.Wong C.X., Abed H.S., Molaee P., et al. Pericardial fat is associated with atrinl fibrillation severity and ablation outcome. J Am Coll Cardiol. 2011;57(17):1745-51. DOI:10.1016/j.jacc.2010.11.045.Wong C.X., Abed H.S., Molaee P., et al. Pericardial fat is associated with atrinl fibrillation severity and ablation outcome. J Am Coll Cardiol. 2011;57(17):1745-51. DOI:10.1016/j.jacc.2010.11.045.O'Connell R.P., Musa H., Gomez M.S., et al. Free fatty acid effects on the atrial myocardium: membrane ionic currents are remodeled by the disruption of T-tubular architecture. PLoS One. 2015;10(8):e0133052. DOI:10.1371/journal.pone.0133052.O'Connell R.P., Musa H., Gomez M.S., et al. Free fatty acid effects on the atrial myocardium: membrane ionic currents are remodeled by the disruption of T-tubular architecture. PLoS One. 2015;10(8):e0133052. DOI:10.1371/journal.pone.0133052.Chilukoti R.K., Giese A., Malenke W., et al. Atrial fibrillation and rapid acute pacing regulate adipocyte/adipositas-related gene expression in the atria. Int J Cardiol. 2015;187:604-13. DOI:10.1016/j.ijcard.2015.03.072.Chilukoti R.K., Giese A., Malenke W., et al. Atrial fibrillation and rapid acute pacing regulate adipocyte/adipositas-related gene expression in the atria. Int J Cardiol. 2015;187:604-13. DOI:10.1016/j.ijcard.2015.03.072.Pouliopoulos J., Chik W.W., Kanthan A., et al. Intramyocardial adiposity after myocardial infarction: new implications of a substrate for ventricular tachycardia. Circulation. 2013;128(21):2296-308. DOI:10.1161/CIRCULATIONAHA.113.002238.Pouliopoulos J., Chik W.W., Kanthan A., et al. Intramyocardial adiposity after myocardial infarction: new implications of a substrate for ventricular tachycardia. Circulation. 2013;128(21):2296-308. DOI:10.1161/CIRCULATIONAHA.113.002238.Filgueiras-Rama D., Arias M.A., Iniesta A., et al. Atrial arrhythmias in obstructive sleep apnea: underlying mechanisms and implications in the clinical setting. Pulm Med. 2013;2013:426758. DOI:10.1155/2013/426758.Filgueiras-Rama D., Arias M.A., Iniesta A., et al. Atrial arrhythmias in obstructive sleep apnea: underlying mechanisms and implications in the clinical setting. Pulm Med. 2013;2013:426758. DOI:10.1155/2013/426758.Genovesi S., Dossi C., Viganт M.R., et al. Electrolyte concentration during haemodialysis and QT intervalprolongation in uraemic patients. Europace. 2008;10:771-7. DOI:10.1093/europace/eun028.Genovesi S., Dossi C., Viganт M.R., et al. Electrolyte concentration during haemodialysis and QT intervalprolongation in uraemic patients. Europace. 2008;10:771-7. DOI:10.1093/europace/eun028.Krijthe B.P., Heeringa J., Kors J.A., et al. Serum potassium levels and the risk of atrial fibrillation:the Rotterdam Study. Int J Cardiol. 2013;168:5411-5. DOI:10.1016/j.ijcard.2013.08.048.Krijthe B.P., Heeringa J., Kors J.A., et al. Serum potassium levels and the risk of atrial fibrillation:the Rotterdam Study. Int J Cardiol. 2013;168:5411-5. DOI:10.1016/j.ijcard.2013.08.048.Lancaster T.S., Schill M.R., Greenberg J.W., et al. Potassium and magnesium supplementation do not protect against atrial fibrillation after cardiac operation: atime-matched analysis. Ann Thorac Surg. 2016;102:1181-8. DOI:10.1016/j.athoracsur.2016.06.066.Lancaster T.S., Schill M.R., Greenberg J.W., et al. Potassium and magnesium supplementation do not protect against atrial fibrillation after cardiac operation: atime-matched analysis. Ann Thorac Surg. 2016;102:1181-8. DOI:10.1016/j.athoracsur.2016.06.066.Lu Y.Y., Cheng C.C., Chen Y.C., et al. Electrolyte disturbancesdifferentially regulate sinoatrial node and pulmonary vein electricalactivity: a contribution to hypokalemiaor hyponatremia-induced atrial fibrillation. Heart Rhythm. 2016;13:781-8. DOI:10.1016/j.hrthm.2015.12.005.Lu Y.Y., Cheng C.C., Chen Y.C., et al. Electrolyte disturbancesdifferentially regulate sinoatrial node and pulmonary vein electricalactivity: a contribution to hypokalemiaor hyponatremia-induced atrial fibrillation. Heart Rhythm. 2016;13:781-8. DOI:10.1016/j.hrthm.2015.12.005.Hyltén-Cavallius L., Iepsen E.W., Christiansen M., et al. Glucose ingestioncauses cardiac repolarization disturbances in type 1 long QT syndrome patients and healthy subjects. Heart Rhythm. 2017;14:1165-70. DOI:10.1016/j.hrthm.2017.04.018.Hyltén-Cavallius L., Iepsen E.W., Christiansen M., et al. Glucose ingestioncauses cardiac repolarization disturbances in type 1 long QT syndrome patients and healthy subjects. Heart Rhythm. 2017;14:1165-70. DOI:10.1016/j.hrthm.2017.04.018.Sinno H., Derakhchan K., Libersan D., et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation. 2003;107:1930-6. DOI:10.1161/01.CIR.0000058743.15215.03.Sinno H., Derakhchan K., Libersan D., et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation. 2003;107:1930-6. DOI:10.1161/01.CIR.0000058743.15215.03.Álvarez-García J., Vives-Borrás M., Gomis P., et al. Electrophysiological effects of selective atrial coronary artery occlusionin humans. Circulation. 2016;133:2235-42. DOI:10.1161/CIRCULATIONAHA.116.021700.Álvarez-García J., Vives-Borrás M., Gomis P., et al. Electrophysiological effects of selective atrial coronary artery occlusionin humans. Circulation. 2016;133:2235-42. DOI:10.1161/CIRCULATIONAHA.116.021700.Viskin S., Golovner M., Malov N., et al. Circadian variation of symptomatic paroxysmalatrial fibrillation. Data from almost 10 000 episodes. Eur Heart J. 1999;20:1429-34. DOI:10.1053/euhj.1999.1632.Viskin S., Golovner M., Malov N., et al. Circadian variation of symptomatic paroxysmalatrial fibrillation. Data from almost 10 000 episodes. Eur Heart J. 1999;20:1429-34. DOI:10.1053/euhj.1999.1632.Gillis A.M., Connolly S.J., Dubuc M., et al. Atrial Pacing Peri-ablation for Prevention of Atrial Fibrillation Trial. Circadian variation of paroxysmal atrial fibrillation. Am J Cardiol. 2001;87:794-8, A8. DOI:10.1016/S0002-9149(00)01509-5.Gillis A.M., Connolly S.J., Dubuc M., et al. Atrial Pacing Peri-ablation for Prevention of Atrial Fibrillation Trial. Circadian variation of paroxysmal atrial fibrillation. Am J Cardiol. 2001;87:794-8, A8. DOI:10.1016/S0002-9149(00)01509-5.Larsen B.S., Kumarathurai P., Nielsen O.W., Sajadieh A. The circadian variationof premature atrial contractions. Europace. 2016;18:1573-80. DOI:10.1093/europace/euv389.Larsen B.S., Kumarathurai P., Nielsen O.W., Sajadieh A. The circadian variationof premature atrial contractions. Europace. 2016;18:1573-80. DOI:10.1093/europace/euv389.Yamashita T., Murakawa Y., Sezaki K., et al. Circadian variation of paroxysmal atrial fibrillation. Circulation. 1997;96:1537-41. DOI:10.1161/01.cir.96.5.1537.Yamashita T., Murakawa Y., Sezaki K., et al. Circadian variation of paroxysmal atrial fibrillation. Circulation. 1997;96:1537-41. DOI:10.1161/01.cir.96.5.1537.Mitchell A.R., Spurrell P.A., Sulke N. Circadian variation of arrhythmiaonset patterns in patients with persistent atrial fibrillation. Am Heart J. 2003;146:902-7. DOI:10.1016/S0002-8703(03)00405-8.Mitchell A.R., Spurrell P.A., Sulke N. Circadian variation of arrhythmiaonset patterns in patients with persistent atrial fibrillation. Am Heart J. 2003;146:902-7. DOI:10.1016/S0002-8703(03)00405-8.Yamashita T., Sekiguchi A., Iwasaki Y.K., et al. Circadian variation of cardiac K+ channelgene expression. Circulation. 2003;107:1917-22. DOI:10.1161/01.CIR.0000058752.79734.F0.Yamashita T., Sekiguchi A., Iwasaki Y.K., et al. Circadian variation of cardiac K+ channelgene expression. Circulation. 2003;107:1917-22. DOI:10.1161/01.CIR.0000058752.79734.F0.Jeyaraj D., Haldar S.M., Wan X., et al. Circadian rhythms govern cardiacrepolarization and arrhythmogenesis. Nature. 2012;483:96-9. DOI:10.1038/nature10852.Jeyaraj D., Haldar S.M., Wan X., et al. Circadian rhythms govern cardiacrepolarization and arrhythmogenesis. Nature. 2012;483:96-9. DOI:10.1038/nature10852.Maesen B., Nijs J., Maessen J., et al. Post-operativeatrial fibrillation: a maze of mechanisms. Europace. 2012;14:159-74. DOI:10.1093/europace/eur208.Maesen B., Nijs J., Maessen J., et al. Post-operativeatrial fibrillation: a maze of mechanisms. Europace. 2012;14:159-74. DOI:10.1093/europace/eur208.Harada M., Van Wagoner D.R., Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J. 2015;79:495-502. DOI:10.1253/circj.CJ-15-0138.Harada M., Van Wagoner D.R., Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J. 2015;79:495-502. DOI:10.1253/circj.CJ-15-0138.Nortamo S., Ukkola O., Lepojärvi S., et al. Association of sST2 and hs-CRP levels withnew-onset atrial fibrillation in coronary artery disease. Int J Cardiol. 2017;248:173-8. DOI:10.1016/j.ijcard.2017.07.022.Nortamo S., Ukkola O., Lepojärvi S., et al. Association of sST2 and hs-CRP levels withnew-onset atrial fibrillation in coronary artery disease. Int J Cardiol. 2017;248:173-8. DOI:10.1016/j.ijcard.2017.07.022.Ishii Y., Schuessler R.B., Gaynor S.L., et al. Postoperativeatrial fibrillation: the role of the inflammatory response. J Thorac Cardiovasc Surg. 2017;153:1357-65. DOI:10.1016/j.jtcvs.2016.12.051.Ishii Y., Schuessler R.B., Gaynor S.L., et al. Postoperativeatrial fibrillation: the role of the inflammatory response. J Thorac Cardiovasc Surg. 2017;153:1357-65. DOI:10.1016/j.jtcvs.2016.12.051.Yao C., Scott L., Veleva T., et al. Enhanced activation of inflammasome promotes atrial fibrillation. J Mol Cell Cardiol. 2017;112:147. DOI:10.1016/j.yjmcc.2017.07.051.Yao C., Scott L., Veleva T., et al. Enhanced activation of inflammasome promotes atrial fibrillation. J Mol Cell Cardiol. 2017;112:147. DOI:10.1016/j.yjmcc.2017.07.051.Ko D., Rahman F., Schnabel R.B., et al. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol. 2016;13:321-32. DOI:10.1038/nrcardio.2016.45.Ko D., Rahman F., Schnabel R.B., et al. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol. 2016;13:321-32. DOI:10.1038/nrcardio.2016.45.Rosano G.M., Leonardo F., Sarrel P.M., et al. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet. 1996;347:786-8. DOI:10.1016/s0140-6736(96)90867-3.Rosano G.M., Leonardo F., Sarrel P.M., et al. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet. 1996;347:786-8. DOI:10.1016/s0140-6736(96)90867-3.Anneken L., Baumann S., Vigneault P., et al. Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking. Eur Heart J. 2016;37:640-50. DOI:10.1093/eurheartj/ehv371.Anneken L., Baumann S., Vigneault P., et al. Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking. Eur Heart J. 2016;37:640-50. DOI:10.1093/eurheartj/ehv371.Watanabe E., Kuno Y., Takasuga H., et al. Seasonal variation in paroxysmal atrial fibrillationdocumented by 24-hour Holter electrocardiogram. Heart Rhythm. 2007;4:27-31. DOI:10.1016/j.hrthm.2006.09.030.Watanabe E., Kuno Y., Takasuga H., et al. Seasonal variation in paroxysmal atrial fibrillationdocumented by 24-hour Holter electrocardiogram. Heart Rhythm. 2007;4:27-31. DOI:10.1016/j.hrthm.2006.09.030.Harada M., Melka J., Sobue Y., Nattel S. Metabolic considerations in atrial fibrillation-mechanistic insights and therapeutic opportunities. Circ J. 2017;81:1749-57. DOI:10.1253/circj.CJ-171058.161.Harada M., Melka J., Sobue Y., Nattel S. Metabolic considerations in atrial fibrillation-mechanistic insights and therapeutic opportunities. Circ J. 2017;81:1749-57. DOI:10.1253/circj.CJ-171058.161.Cardin S., Guasch E., Luo X., et al. Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol. 2012;5:1027-35. DOI:10.1161/CIRCEP.112.973214.Cardin S., Guasch E., Luo X., et al. Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol. 2012;5:1027-35. DOI:10.1161/CIRCEP.112.973214.Luo X., Pan Z., Shan H., et al. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest. 2013;123:1939-51. DOI:10.1172/JCI62Luo X., Pan Z., Shan H., et al. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest. 2013;123:1939-51. DOI:10.1172/JCI62Luo X., Yang B., Nattel S. MicroRNAs and atrial fibrillation: mechanisms and translational potential. Nat Rev Cardiol. 2015;12:80-90. DOI:10.1038/nrcardio.2014.178.Luo X., Yang B., Nattel S. MicroRNAs and atrial fibrillation: mechanisms and translational potential. Nat Rev Cardiol. 2015;12:80-90. DOI:10.1038/nrcardio.2014.178.Van den Berg N.W.E., Kawasaki M., Berger W.R., et al. MicroRNAs in atrial fibrillation: from expression signatures to functional implications. Cardiovasc Drugs Ther. 2017;31:345-65. DOI:10.1007/s10557-017-6736-z.Van den Berg N.W.E., Kawasaki M., Berger W.R., et al. MicroRNAs in atrial fibrillation: from expression signatures to functional implications. Cardiovasc Drugs Ther. 2017;31:345-65. DOI:10.1007/s10557-017-6736-z.Amit G., Kikuchi K., Greener I.D., et al. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation. 2010;121:2263-70. DOI:10.1161/CIRCULATIONAHA.109.911156.Amit G., Kikuchi K., Greener I.D., et al. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation. 2010;121:2263-70. DOI:10.1161/CIRCULATIONAHA.109.911156.Bikou O., Thomas D., Trappe K., et al. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res. 2011;92:218-25. DOI:10.1093/cvr/cvr209.Bikou O., Thomas D., Trappe K., et al. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res. 2011;92:218-25. DOI:10.1093/cvr/cvr209.Igarashi T., Finet J.E., Takeuchi A., et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation. 2012;125:216-25. DOI:10.1161/CIRCULATIONAHA.111.053272.Igarashi T., Finet J.E., Takeuchi A., et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation. 2012;125:216-25. DOI:10.1161/CIRCULATIONAHA.111.053272.Trappe K., Thomas D., Bikou O., et al. A. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. Eur Heart J. 2013;34:147-57. DOI:10.1093/eurheartj/ehr269.Trappe K., Thomas D., Bikou O., et al. A. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. Eur Heart J. 2013;34:147-57. DOI:10.1093/eurheartj/ehr269.Hammoudi N., Ishikawa K., Hajjar R. J. Adeno-associated virus-mediated gene therapy in cardiovascular disease. Curr OpinCardiol. 2015;30:228-34. DOI:10.1097/HCO.0000000000000159.Hammoudi N., Ishikawa K., Hajjar R. J. Adeno-associated virus-mediated gene therapy in cardiovascular disease. Curr OpinCardiol. 2015;30:228-34. DOI:10.1097/HCO.0000000000000159.Greenberg B., Butler J., Felker G.M., et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016;387:1178-86. DOI:10.1016/S0140-6736(16)00082-9.Greenberg B., Butler J., Felker G.M., et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016;387:1178-86. DOI:10.1016/S0140-6736(16)00082-9.Tadevosyan A., Vaniotis G., Allen B.G., et al. G proteincoupled receptor signalling in the cardiac nuclear membrane: evidence and possible roles in physiological and pathophysiological function. J Physiol. 2012;590:1313-30. DOI:10.1113/jphysiol.2011.222794.Tadevosyan A., Vaniotis G., Allen B.G., et al. G proteincoupled receptor signalling in the cardiac nuclear membrane: evidence and possible roles in physiological and pathophysiological function. J Physiol. 2012;590:1313-30. DOI:10.1113/jphysiol.2011.222794.Tadevosyan A., Xiao J., Surinkaew S., et al. Intracellular angiotensinII interacts with nuclear angiotensin receptors in cardiac fibroblasts and regulates RNA synthesis, cell proliferation, and collagen secretion. J Am Heart Assoc. 2017;6:e004965. DOI:10.1161/JAHA.116.004965.Tadevosyan A., Xiao J., Surinkaew S., et al. Intracellular angiotensinII interacts with nuclear angiotensin receptors in cardiac fibroblasts and regulates RNA synthesis, cell proliferation, and collagen secretion. J Am Heart Assoc. 2017;6:e004965. DOI:10.1161/JAHA.116.004965.Audet N., Dabouz R., Allen B..G, Hebert T.E. Nucleoligands-repurposing GPCR ligands to modulate nuclear-localized GPCRs in the cardiovascular system. J Cardiovasc Pharmacol. 2018;71(4):193204. DOI:10.1097/FJC.0000000000000535.Audet N., Dabouz R., Allen B..G, Hebert T.E. Nucleoligands-repurposing GPCR ligands to modulate nuclear-localized GPCRs in the cardiovascular system. J Cardiovasc Pharmacol. 2018;71(4):193204. DOI:10.1097/FJC.0000000000000535.Канорский С.Г. Антиаритмическая терапия у больных с пароксизмальной и персистирующей формой фибрилляции предсердий, определение достижимой цели и оценка имеющихся средств. Кардиология. 2014;2:70-4.Kanorsky S.G. Antiarrhythmic therapy in patients with a paroxysmal and persistent form of atrial fibrillation, determining an achievable goal and evaluating available funds. Kardiologiia. 2014;2:70-4 (In Russ.)

The authors declare that there are no conflicts of interest present.